CClinicalTrials.gg
Status unknownNCT03290690Updated Mar 6, 2020

Positive Predictive Value (PPV) of Pseudomonas Aeruginosa

An observational study in Wound, Chronic Leg Ulcer and Wound Contamination, sponsored by MolecuLight Inc.. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by MolecuLight Inc. · Observational

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
18 Years and older
Sex
All
01

Study summary

This is a non-randomized, single-blind post market clinical follow-up study for which 65 patients will be imaged at Rouge Valley Centenary Hospital (Scarborough and Rouge Hospital) who present with a chronic wound and are receiving standard wound care treatment. The MolecuLight i:X imaging device will be used by the study clinician as an adjunctive tool in the assessment of the wound and will be used to guide the targeted sampling of a wound (with curettage scraping), as per current standard of care in the principal investigator's wound care clinic. The acquired tissue sample will then be analysed using conventional gold standard semi-quantitative culture methods to determine bacterial species present, also as per current standard of care in this clinic.

02

Conditions studied

  • Wound
  • Chronic Leg Ulcer
  • Wound Contamination
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be treated at the Scarborough and Rouge Hospital as per the standard of care, which includes use of the MolecuLight i:X imaging device and targeted sampling of regions with bacterial fluorescence for microbiological analysis. Patients will be identified as candidates and consented by the study's principle investigator. The images which would be acquired for this study are currently part of the routine clinical wound care assessment process in the principle investigator's wound care clinic. However, during study enrollment subjects will be given as much time as required for their understanding of the basic study, to understand that their participation is optional, to understand that they will receive standard of care wound treatment whether or not they choose to participate, and to have any potential questions addressed.

Inclusion criteria

  1. Male or female patients presenting with a chronic wound (wound duration > 4 weeks) e.g. diabetic foot ulcer, venous leg ulcer, pressure ulcer, or other acceptable aetiology
  2. 18 years or older

Exclusion criteria

Exclusion Criteria:

  1. Treatment with an investigational drug within 1 month before study enrolment
  2. Inability to consent to medical photography (i.e. inability to understand consent process)
  3. Any contra-indication to routine wound care and/or monitoring
  4. Prior participation of the patient in this study (for the same wound or a different wound).
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (estimated)
Patient registry
No

Groups and cohorts

  • All Subjects

    All subjects in this study will have their wounds imaged and assessed in the following manner: Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form

05

What researchers measure

Primary outcomes

  1. Evaluate the ability of the MolecuLight i:X Imaging Device to predicting the presence of Pseudomonas aeruginosa in chronic wounds

    Primary endpoint: correlation of localized cyan fluorescence signals in device acquired images with microbiological samples indicating Pseudomonas aeruginosa

    Time frame: 1 hour

06

Study locations

1 of 1 sites recruiting
  • Scarborough and Rouge Hospital
    Scarborough, Ontario M1E 4B9, Canada
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03290690
Lead sponsor
MolecuLight Inc.
Collaborators
Scarborough Rouge Hospital
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Aug 4, 2017
Primary completion
Jul 30, 2020 (estimated)
Completion
Jul 30, 2020 (estimated)
Last update
Mar 6, 2020

Study contacts

Liis Teene
Contact
lteene@moleculight.com
6472551519
Rose Raizman
Contact
rraizman@rougevalley.ca
416-886-2328
Rose Raizman
principal investigator · Scarborough Rouge Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion